Drugs /

milademetan tosylate

Back to Drugs List

Overview

NCI Definition [1]:
An orally available MDM2 (murine double minute 2) antagonist with potential antineoplastic activity. Upon oral administration, MDM2 inhibitor DS-3032b binds to, and prevents the binding of MDM2 protein to the transcriptional activation domain of the tumor suppressor protein p53. By preventing this MDM2-p53 interaction, the proteosome-mediated enzymatic degradation of p53 is inhibited and the transcriptional activity of p53 is restored. This results in the restoration of p53 signaling and leads to the p53-mediated induction of tumor cell apoptosis. MDM2, a zinc finger protein and a negative regulator of the p53 pathway, is overexpressed in cancer cells; it has been implicated in cancer cell proliferation and survival.

Clinical Trials

View Clinical Trials for milademetan tosylate

Milademetan tosylate has been investigated in 2 clinical trials, of which 0 are open and 2 are closed. Of the trials investigating milademetan tosylate, 2 are phase 1 (0 open).

FLT3 ITD is the most frequent biomarker inclusion criterion for milademetan tosylate clinical trials.

Acute myeloid leukemia, secondary acute myeloid leukemia, and therapy-related acute myeloid leukemia are the most common diseases being investigated in milademetan tosylate clinical trials [2].

Top Biomarker Inclusion Criteria for Closed Clinical Trials Investigating Milademetan Tosylate
This graph displays the 20 most frequently occurring biomarkers curated on clinical trials investigating milademetan tosylate and the cancer types associated with these biomarkers. These numbers are derived from a set of 5,956 clinical trials for which biomarker status defines treatment.

Drug Details

Synonyms [2]:
mdm2 inhibitor ds-3032b, ds-3032b, hdm2 inhibitor ds-3032b, hdm2 inhibitor ds-3032b, ds-3032 tosylate, ds-3032b tosylate
Drug Target(s) [2]:
MDM2
NCIT ID [1]:
C107384

References

1. National Cancer Institute. NCI Thesaurus Version 18.11d. https://ncit.nci.nih.gov/ncitbrowser/. [2018-07-30] [2018-08-02].

2. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.